Pérez-Camacho Inés, Camacho Angela, Torre-Cisneros Julián, Rivero Antonio
Servicio de Medicina Interna, Hospital de Poniente, El Ejido, Almería, España.
Enferm Infecc Microbiol Clin. 2009 Sep;27 Suppl 1:24-32. doi: 10.1016/S0213-005X(09)73442-1.
HIV-infected patients share traditional cardiovascular risk factors with the general population. Moreover, HIV per se significantly increases the risk of cardiovascular disease. Consequently, control of HIV infection with highly-active antiretroviral therapy (HAART) helps to reduce vascular risk in HIV-infected patients. However, there is evidence that HAART increases cardiovascular risk and the use of abacavir, didanosine, lopinavir/ritonavir and indinavir has been associated with the development of acute myocardial infarction (AMI). However, the absolute risk of AMI in patients receiving HAART is very low in relation to the benefit obtained with antiretroviral therapy.
感染HIV的患者与普通人群具有相同的传统心血管危险因素。此外，HIV本身会显著增加心血管疾病的风险。因此，采用高效抗逆转录病毒疗法（HAART）控制HIV感染有助于降低HIV感染患者的血管风险。然而，有证据表明HAART会增加心血管风险，使用阿巴卡韦、去羟肌苷、洛匹那韦/利托那韦和茚地那韦与急性心肌梗死（AMI）的发生有关。然而，接受HAART治疗的患者发生AMI的绝对风险与抗逆转录病毒治疗所获得的益处相比非常低。
